Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abvc Biopharma Inc (NQ: ABVC )

0.6661 -0.0052 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,772
Open 0.6700
Bid (Size) 0.6300 (10)
Ask (Size) 0.7900 (3)
Prev. Close 0.6713
Today's Range 0.6501 - 0.6715
52wk Range 0.5000 - 2.100
Shares Outstanding 24,420,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
+11.02%
+11.02%
1 Month
-11.19%
-11.19%
3 Month
-0.95%
-0.95%
6 Month
-11.07%
-11.07%
1 Year
-67.82%
-67.82%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
What's happening With ABVC BioPharma Shares?
Via Benzinga
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
Via NewMediaWire
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
Via NewMediaWire
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand
Via NewMediaWire
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
Via NewMediaWire
ABVC BioPharma Provides 2023 Pipeline Update
Via NewMediaWire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Via NewMediaWire
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus (R)
Via NewMediaWire
Exposures Product Safety
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
Via NewMediaWire
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Dow Falls Over 200 Points; Walgreens Earnings Top Expectations
Via Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Down Over 100 Points; Crude Oil Rises 1%
Via Benzinga
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
Via NewMediaWire
Exposures Product Safety
SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud
Via Benzinga
ABVC BioPharma Provides Vitargus Update - Phase II Vitargus Study Protocol Received Thai FDA Approval
Via NewMediaWire
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.